JUN 16, 2016 10:13 AM PDT

Alzheimer's Disease: The Role of Presenilin 2

WRITTEN BY: Cassidy Reich
Alzheimer’s disease (AD) currently affects 5.5 million people in the U.S. over the age of 65, and that number will continue to grow unless a disease-modifying therapy is created. Even though there is a ton of research going on in the Alzheimer’s field, there are still some astounding gaps in our basic knowledge of disease pathology. It will be very difficult, if not impossible, to create the kind of disease-modifying therapy we so desperately need without a full understanding of the changes happening at the cellular level. With this in mind, a recent paper published in Cell is very exciting because it fills in a gap in our basic Alzheimer’s disease knowledge.

             
Wim Annaert’s group at KU Leuven in Belgium published a beautiful series of experiments that described the differences between presenilin 1 and presenilin 2. Presenlins are the catalytic subunit of γ-secretase, the second protease that cuts the amyloid precursor protein (APP) to form amyloid-β, the toxic peptide that accumulates in AD. Amyloid- β (Aβ) comes in a few different lengths, but for right now, we will just focus on two, Aβ40 and Aβ42. Aβ42 is considered more toxic than Aβ40 because it is more prone to aggregation, and in AD, the ratio of Aβ42:Aβ40 is much higher than in a healthy brain. There are mutations in presenilin 1 (PSEN1) that lead to higher Aβ42:Aβ40 ratios and those mutations cause familial AD. There are also some mutations in presenilin 2 (PSEN2) that lead to familial AD. Since there are only 13 known AD-causing mutations in PSEN2 compared to the over 180 known AD-causing mutations in PSEN1, most of the AD research on the γ-secretase complex has focused on PSEN1.

This new research shows that while PSEN1 is distributed among all cellular compartments, PSEN2 is localized to membranes in the endolysosomal system. The specific localization to the endolysosomal system is significant in the context of AD pathology because there is increasing evidence that endosomal dysfunction is one of the earliest pathological events in sporadic AD.

APP is cleaved by γ-secretase on endosomal membranes which generates intraneuronal Aβ. A lot of AD research has focused on extracellular Aβ in the context of plaques and synaptotoxic oligomers, but intraneuronal accumulation of Aβ plays a role in disease pathology as well. What’s more, intraneuronal pools of Aβ have a higher Aβ42:Aβ40 ratio than extracellular pools. Why exactly this is the case is unclear, but Ralph Nixon at NYU (who was unaffiliated with this study in Cell), suggests that it might be because the aggregation-prone Aβ42 is more resistant to the acidic environment in the lysosomes so it accumulates instead of being degraded like Aβ40.  

            
The researchers also investigated some of the known mutations in PSEN1 and PSEN2. The PSEN2 mutations did not change its localization to the endolysosomal system, but they did increase the Aβ42:Aβ40 even more. In the case of one tested mutation, the ratio of intraneuronal Aβ42 to Aβ40 was 50:1 (the normal ratio in a healthy brain is 1:9). Interestingly, they also saw that two of the known AD-causing mutations in PSEN1 that they tested changed the localization of PSEN1 so that it looked like PSEN2. The mutated PSEN1 was localized to the endolysosomal system and generated intraneuronal Aβ42. This confirms that the intraneuronal Aβ42 accumulation plays a role in AD pathology by way of a malfunctioning endolysosomal system.

This is the kind of fundamental research that we need to get a more complete picture of the early pathology in AD. If we want a disease-modifying therapy, it will most likely be most effective in the early disease stages. Understanding what is happening at this stage of disease pathology is the first step in designing a therapy to fight it.  

Sources: AlzForum, Cell, and Frontiers in Physiology
About the Author
  • Cassidy is a curious person, and her curiosity has led her to pursue a PhD in Pharmacology at the New York University Sackler Institute of Biomedical Sciences. She likes to talk about science way too much, so now she's going to try writing about it.
You May Also Like
SEP 17, 2019
Cell & Molecular Biology
SEP 17, 2019
Insight Into a Common Mechanism Underlying Some Neurodevelopmental Disorders
Mutations impacting a protein complex called SWI/SNF can cause a variety of problems. Now researchers know more about why....
SEP 17, 2019
Drug Discovery
SEP 17, 2019
Does Microdosing Really Boost Productivity and Creativity?
Microdosing is the practice of ingesting very low doses of psychedelic substances, typically a twentieth of a recreational dose. In particular, Lysergic ac...
SEP 17, 2019
Genetics & Genomics
SEP 17, 2019
The Genetic Reasons You're Addicted to Smoking
Addiction to cigarettes, or nicotine, is one of the most widely researched addictions in modern science. And this is no surprise. Over 1.1 billion people a...
SEP 17, 2019
Drug Discovery
SEP 17, 2019
Drug Targets Early Instigators of Alzheimer Disease
The two solidifying instigators of Alzheimer -disease (AD)—amyloid beta and the tau protein—have long been the topic of study for AD researcher...
SEP 17, 2019
Genetics & Genomics
SEP 17, 2019
The Genetic Reasons Why Some People Need Less Sleep
Typically, people need between seven and eight hours of sleep per night to function properly. In  fact, reducing sleep by just one or two hours for a ...
SEP 17, 2019
Neuroscience
SEP 17, 2019
Neuroscientists create a stunning digital map of 1,000 neurons
Two years ago, Dr. Jayaram Chandrashekar and his colleagues at the Howard Hughes Medical Institute's Janelia Research Campus sought out to map the mouse brain as intricately as possible. Now,...
Loading Comments...